Summary
Previous strategies for stabilizing combi-triazenes were based on masking the 1,2,3-triazene chain with a 3-acetoxymethylene group. The half-lives of the latter molecules were only ca 5 min longer than those of their parent 1,2,3-triazenes. The novel combi-molecules described herein contain a hydrolysable carbamate group that modulates their kinetics of degradation. Their half-lives were prolonged by ca 20–55 min when compared with their acetoxymethyltriazene counterparts. While they decomposed slowly in serum-containing medium, their intracellular decomposition was extremely rapid. They blocked EGFR tyrosine kinase in an isolated enzyme assay and in MDA-MB-468 breast cancer cells. Similarly, they all induced a dose-dependent DNA damage and G2/M cell cycle arrest in MDA-MB-468 cells, except the most stable compound ZRL2 (a 3-vinyl carbamate). ZRL4 (a chloromethyl carbamate) was the most potent and ZRL2 was the least active of the series against MDA-MB-468 cells. In selectivity assay with NIH-3T3 and NIH-3T3/HER-14, all compounds selectively blocked proliferation of NIH-3T3/HER-14. ZRS1 exerted the strongest growth inhibitory potency of the series. The results in toto suggest that ZRL2, despite being the most stable compound, could not hydrolyze at a rate that permitted the generation of DNA damaging species, thereby behaving primarily as an EGFR inhibitor. Thus the study permitted the definition of an optimized combi-molecule as one that decomposes at a rate that is slower than that of acetoxymethyltriazenes, but rapid enough to generate strong EGFR-DNA targeting potential and growth inhibition. Based on the latter criteria, ZRS1 and ZRL4 were tested in vivo and ZRS1 has proven the more effective.
Similar content being viewed by others
References
Argawal A, Gutteridge E, Gee JMW, Nicholson RI, Robertson JFR (2005) Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12:S135–S144
Biscardi JS, Ishizawar RC, Silva CM, Parsone SJ (2000) Tyrosine kinase signaling in breast cancer epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2:203–10
Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF et al (1994) Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117–125
Lo H, Hsu S, Hung M (2006) EGFR signaling pathway in breast cancer: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95:211–18
Rewcastle GW, Denny WA, Bridges AJ, Hairong Z, Cody DR, McMichael A et al (1995) Tyrosine kinase inhibitor. 5. Synthesis and structure-activity relationships for 4- [(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 38:3482–3487
Moore S, Cobleigh MA (2007) Treating metastatic and advanced cancer. Sem Oncol Nursing 23:37–45
Rachid Z, Brahimi F, Qiu Q, Williams C, Hartley JM, Hartley JA et al (2007) Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexpressing solid tumors: Discovery of an Unusual Structure-Activity Relationship. J Med Chem 50:2605–2608
Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee JP et al (2007) The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res 13:331–340
Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ (2007) Type II combi-molecules: design and binary targeting properties of the novel triazoliniumcontaining molecules JDD36 and JDE05. Anticancer Drugs 18:171–177
Merayo N, Rachid Z, Qiu Q, Brahimi F, Jean-Claude BJ (2006) The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anticancer Drugs 17:165–171
Domarkas J, Dudouit F, Williams C, Qiu Q, Banerjee R, Brahimi F et al (2006) The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 49:3544–3552
Rachid Z, Brahimi F, Domarkas J, Jean-Claude BJ (2005) Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Bioorg Med Chem Lett 15:1135–1138
Katsoulas A, Rachid Z, Brahimi F, McNamee JP, Jean-Claude BJ (2005) Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl. Leuk Res 29:565–572
Katsoulas A, Rachid Z, Brahimi F, McNamee JP, Jean-Claude BJ (2005) Engineering 3- alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcrabl expressing leukemias. Leuk Res 29:693–700
Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ (2005) Mechanism of action of a novel “combi-triazene” engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol 70:511–519
Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ (2004) Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate 59:13–21
Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ (2004) The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharm Exp Ther 311:1163–1170
Matheson SL, Brahimi F, Jean-Claude BJ (2004) The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting “combi-triazene” SMA41. Biochem Pharmacol 67:1131–1138
Matheson SL, Qiu Q, Brahimi F, Dudouit F, Banerjee R, Rachid Z et al (2004) Combimolecules: a global approach towards better chemoselectivity of cytotoxic agents and chemoresistance of refractory tumors. Bull Cancer 91:911–915
Brahimi F, Rachid Z, Qiu Q, McNamee JP, Li Y-J, Tari AM et al (2004) Multiple mechanisms of action of ZR2002 in human breast cancer cells: A novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer 112:484–491
Banerjee R, Rachid Z, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ (2004) Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br J Cancer 91:1066–1073
Banerjee R, Rachid Z, McNamee JP, Jean-Claude BJ (2003) Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and an alkylating agent: a novel tumour targeting concept. J Med Chem 46:5546–51
Banerjee R, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ (2004) Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br J Cancer 91:1066–73
Rachid Z, MacPhee M, Williams C, Todorova M, Jean-Claude BJ (2009) Design and synthesis of new stabilized combi-triazenes for targeting solid tumours expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg Chem Lett 19:5505–5509
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947
Qiu Q, Larroque AL, Gibbs BF, Fang JY, Lakhrissi Y, Soucy J-P et al (2009) Molecular analysis of the in vivo metabolism and biodistribution of metabolically and nonmetabolically activated combi molecules of the triazene class. Drug Met Lett 3:1–9
Banerjee R (2006) A novel small molecule-based multi-targeting approach for the selective therapy of epidermal growth factor receptor (EGFR)- or HER2-expressing carcinomas. Ph.D thesis, McGill University
Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ (2003) The combi-targeting concept: chemical dissection of the dual targeting properties of a series of “combitriazenes”. J Med Chem 46:4313–4321
Matheson S, McNamee JP, Jean-Claude BJ (2003) Differential responses of EGFR-/AGT-expressing cells to the “combi-triazene” SMA41. Cancer Chemother Pharmacol 51(1):11–20
Acknowledgements
We thank the Canadian Institute of Health Research (CIHR) for financial support (Grant No. FRN 49440).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
MacPhee, M., Rachid, Z., Todorova, M. et al. Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest New Drugs 29, 833–845 (2011). https://doi.org/10.1007/s10637-010-9431-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9431-5